Molecular Variability in Levodopa Absorption and Clinical Implications for the Management of Parkinson's Disease

被引:1
作者
de Menezes, Ana Luisa Pedrosa
Bloem, Bastiaan R.
Beckers, Milan
Piat, Capucine
Benarroch, Eduardo E.
Savica, Rodolfo [1 ]
机构
[1] Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA
关键词
Levodopa; absorption; Parkinson's disease; transport; molecular pathway; AMINO-ACID-TRANSPORT; THYROID-HORMONE TRANSPORT; MESSENGER-RNA EXPRESSION; CARRIER-MEDIATED TRANSPORT; BLOOD-BRAIN-BARRIER; L-DOPA; INTESTINAL-ABSORPTION; INDUCED DYSKINESIA; ASCORBIC-ACID; MICE LACKING;
D O I
10.3233/JPD-240036
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Levodopa is the most widely used medication for the symptomatic treatment of Parkinson's disease and, despite being an "old" drug, is still considered the gold standard for offering symptomatic relief. The pharmacokinetic and pharmacodynamics of levodopa have been studied extensively. Our review explores the molecular mechanisms that affect the absorption of this drug, focusing on the large intra- and interindividual variability of absorption that is commonly encountered in daily clinical practice, and on the interaction with other medications. In addition, we will explore the clinical implications of levodopa absorption variability and address current and future strategies for researchers and clinicians.
引用
收藏
页码:1353 / 1368
页数:16
相关论文
共 138 条
[1]   Levodopa: the story so far [J].
Abbott, Alison .
NATURE, 2010, 466 (7310) :S6-S7
[2]   Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease [J].
Adibi, SA .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2003, 285 (05) :G779-G788
[3]  
Ahlskog J.E., 2015, The New Parkinson's Disease Treatment Book: Partnering with Your Doctor to Get the Most from Your Medications
[4]   Relationship between absolute and relative ratios of glutamate, glutamine and GABA and severity of autism spectrum disorder [J].
Al-Otaish, Hanoof ;
Al-Ayadhi, Laila ;
Bjorklund, Geir ;
Chirumbolo, Salvatore ;
Urbina, Mauricio A. ;
El-Ansary, Afaf .
METABOLIC BRAIN DISEASE, 2018, 33 (03) :843-854
[5]   BETA(2)-ADRENERGIC AGONIST AS ADJUNCT THERAPY TO LEVODOPA IN PARKINSONS-DISEASE [J].
ALEXANDER, GM ;
SCHWARTZMAN, RJ ;
NUKES, TA ;
GROTHUSEN, JR ;
HOOKER, MD .
NEUROLOGY, 1994, 44 (08) :1511-1513
[6]  
Allikmets L H, 1978, Ann Ist Super Sanita, V14, P63
[7]  
[Anonymous], U.S. Bureau of Economic Analysis. U.S. Department of Commerce. Retrieved April 21, 2024 from https://www.bea.gov/
[8]   CLINICAL AND PHARMACOKINETIC EFFECTS OF A DIET RICH IN INSOLUBLE FIBER ON PARKINSON DISEASE [J].
ASTARLOA, R ;
MENA, MA ;
SANCHEZ, V ;
DELAVEGA, L ;
DEYEBENES, JG .
CLINICAL NEUROPHARMACOLOGY, 1992, 15 (05) :375-380
[9]   PHARMACOKINETICS AND TEMPERATURE [J].
BALLARD, BE .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1974, 63 (09) :1345-1358
[10]   Oral gabapentin disposition in patients with epilepsy after a high-protein meal [J].
Benetello, P ;
Furlanut, M ;
Fortunato, M ;
Baraldo, M ;
Pea, F ;
Tognon, A ;
Testa, G .
EPILEPSIA, 1997, 38 (10) :1140-1142